Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This is an open access book. The objectives of the conference are as follows. to update knowledge about the relevant program priorities for addressing CVD burden in developing countries to explore options for the comprehensive management of primary cardiovascular risk factors such as high blood pressure, high blood glucose level, smoking, and sedentary lifestyle to discuss the latest guidance and evidence on the early detection and management of CVD and its implementation in the context of developing countries, including the impact of the COVID-19 pandemic on the management of CVD to strengthen interprofessional collaboration in addressing challenges using multidisciplinary approaches for the prevention, treatment, and rehabilitation of patients with CVD to update knowledge about health technology science and innovation related to the management and rehabilitation of patients with CVD.

Cardiovascular system --- Diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The purpose of this issue is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease. The topic focuses on the improvements in disease outcomes as well as the numerous beneficial effects of use of certain medications such as GLP-1 agonists, dual GLP-1/ GIP agonists, and SGLT-2 inhibitors for diabetes mellitus treatment; PCSK9 inhibitors and small interfering RNA (siRNA) molecules for dyslipidemia; and antiaggregants, oral anticoagulants, scubitril/valsartan, and non-steroidal mineralocorticoid receptor agonists or dapagliflozin in cardiovascular diseases. We believe that the number of real-life studies and in vivo and in vitro research of the effects of these drugs is quite low at the moment, leading to a lack of understanding of the complex molecular effects and pleiotropic effects of these medications, as well as incomplete knowledge regarding the repurposing of these drugs in clinical practice. Thus, this Special Issue is incredibly topical and important, and we look forward to your submissions which will help to clarify the issues surrounding such drugs.

Cardiovascular system --- Diseases.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The purpose of this issue is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease. The topic focuses on the improvements in disease outcomes as well as the numerous beneficial effects of use of certain medications such as GLP-1 agonists, dual GLP-1/ GIP agonists, and SGLT-2 inhibitors for diabetes mellitus treatment; PCSK9 inhibitors and small interfering RNA (siRNA) molecules for dyslipidemia; and antiaggregants, oral anticoagulants, scubitril/valsartan, and non-steroidal mineralocorticoid receptor agonists or dapagliflozin in cardiovascular diseases. We believe that the number of real-life studies and in vivo and in vitro research of the effects of these drugs is quite low at the moment, leading to a lack of understanding of the complex molecular effects and pleiotropic effects of these medications, as well as incomplete knowledge regarding the repurposing of these drugs in clinical practice. Thus, this Special Issue is incredibly topical and important, and we look forward to your submissions which will help to clarify the issues surrounding such drugs.

Cardiovascular system --- Diseases.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The goal of this Special Issue is to disseminate emerging techniques and innovative solutions that comprehensively address unmet needs in cardiovascular disease and can be rapidly translated into the clinical arena in order to significantly improve diagnostic accuracy and precision in treatment delivery, as well as to enhance therapy guidance and procedural success. The volume includes research contributions from cross-disciplinary scientists and professionals who work in the cardiovascular field at the interface of basic and translational research, clinical practice, medical (bio)physics, engineering, mathematics, and computer science. Several compelling contributions are focused on the development of advanced techniques in cardiovascular imaging (MRI, CT, ultrasound, optics) to investigate structure-function interaction and identify pathology, image analysis (e.g. registration, segmentation, visualization), deep-learning/AI classification methods to better characterize tissue and physiological signals, novel preclinical experimental models and clinical approaches employed in electro-anatomical mapping and image-aided therapies (e.g., cardiac ablation, resynchronization), as well as innovative interventional procedures for vascular applications.

Cardiovascular system --- Diseases. --- Cardiovascular diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The present Special Issue will lead you to discover the association between cardiovascular and metabolic diseases, through update reviews and original articles exploring the pathophysiological mechanisms underpinning this association and describing the latest results in term of cardiovascular event prevention. An interesting scientific journey that reflects the recent advances in pharmacological treatments and interventional procedures.

Cardiovascular system --- Diseases --- Alternative treatment.